BG62913B1 - Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане - Google Patents
Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане Download PDFInfo
- Publication number
- BG62913B1 BG62913B1 BG102644A BG10264498A BG62913B1 BG 62913 B1 BG62913 B1 BG 62913B1 BG 102644 A BG102644 A BG 102644A BG 10264498 A BG10264498 A BG 10264498A BG 62913 B1 BG62913 B1 BG 62913B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- infusion
- solutions
- additives
- mmol
- hypersensitivity reactions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19604095 | 1996-01-25 | ||
PCT/DE1997/000170 WO1997026862A2 (fr) | 1996-01-25 | 1997-01-27 | Solutions concentrees ameliorees pour injection et perfusion a administrer par voie intraveineuse |
Publications (2)
Publication Number | Publication Date |
---|---|
BG102644A BG102644A (en) | 1999-06-30 |
BG62913B1 true BG62913B1 (bg) | 2000-11-30 |
Family
ID=7784538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102644A BG62913B1 (bg) | 1996-01-25 | 1998-07-21 | Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане |
Country Status (21)
Country | Link |
---|---|
US (1) | US6638913B1 (fr) |
EP (1) | EP0876140B1 (fr) |
JP (1) | JP2000505789A (fr) |
KR (1) | KR100505772B1 (fr) |
CN (1) | CN1209751A (fr) |
AT (1) | ATE251893T1 (fr) |
AU (1) | AU2150497A (fr) |
BG (1) | BG62913B1 (fr) |
BR (1) | BR9707081A (fr) |
CA (1) | CA2244209C (fr) |
CZ (1) | CZ234898A3 (fr) |
DE (2) | DE19703816A1 (fr) |
DK (1) | DK0876140T3 (fr) |
ES (1) | ES2208884T3 (fr) |
HU (1) | HUP9901355A3 (fr) |
IL (1) | IL124676A0 (fr) |
NO (1) | NO983438L (fr) |
PL (1) | PL328199A1 (fr) |
PT (1) | PT876140E (fr) |
SK (1) | SK101398A3 (fr) |
WO (1) | WO1997026862A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
CA2298475A1 (fr) | 1997-10-31 | 1999-05-14 | Walter Reed Army Institute Of Research | Procede permettant d'inhiber les effets secondaires de compositions pharmaceutiques contenant des excipients amphiphiles ou des molecules vecteurs de medicaments |
HU229993B1 (en) | 1998-04-01 | 2015-04-28 | Cardiome Pharma Corp | Aminocyclohexyl ether compounds and uses thereof |
US7524879B2 (en) | 2000-10-06 | 2009-04-28 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
DE10115740A1 (de) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
US20020169112A1 (en) * | 2001-05-08 | 2002-11-14 | Luc Montagnier | Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
ES2264776T3 (es) | 2003-05-02 | 2007-01-16 | Cardiome Pharma Corp. | Compuestos de aminociclohexil eter y sus usos. |
US7345087B2 (en) | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
US8058304B2 (en) | 2004-04-01 | 2011-11-15 | Cardiome Pharma Corp. | Merged ion channel modulating compounds and uses thereof |
US7977373B2 (en) | 2004-04-01 | 2011-07-12 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
WO2006053037A2 (fr) | 2004-11-08 | 2006-05-18 | Cardiome Pharma Corp. | Schemas posologiques pour composes de modulation de canaux ioniques |
US20060270708A1 (en) * | 2005-05-25 | 2006-11-30 | Navinta Llc | Novel process for preparation of isotonic aqueous injection of ropivacaine |
EP1897535A1 (fr) * | 2006-08-30 | 2008-03-12 | Dirinco AG | Liquide substitue pour haemoflitration |
US20090239894A1 (en) * | 2008-03-20 | 2009-09-24 | Bjorn Schurad | Stabilized aqueous solutions of ergoline compounds |
JP2012519706A (ja) | 2009-03-06 | 2012-08-30 | ジェネンテック, インコーポレイテッド | 抗体製剤 |
US10634741B2 (en) * | 2009-12-04 | 2020-04-28 | Endomagnetics Ltd. | Magnetic probe apparatus |
US9427186B2 (en) * | 2009-12-04 | 2016-08-30 | Endomagnetics Ltd. | Magnetic probe apparatus |
NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
CN102319258B (zh) * | 2011-08-04 | 2012-10-31 | 山西诺成制药有限公司 | 一种5%葡萄糖置换液及其制备方法 |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
AU2014229811B2 (en) | 2013-03-11 | 2018-02-15 | Endomagnetics Ltd. | Hypoosmotic solutions for lymph node detection |
US9234877B2 (en) | 2013-03-13 | 2016-01-12 | Endomagnetics Ltd. | Magnetic detector |
US9239314B2 (en) | 2013-03-13 | 2016-01-19 | Endomagnetics Ltd. | Magnetic detector |
WO2014158965A1 (fr) * | 2013-03-27 | 2014-10-02 | Ge Healthcare As | Procédé et réactif pour préparer une composition diagnostique |
EP3302338B1 (fr) | 2015-06-04 | 2020-09-30 | Endomagnetics Ltd. | Matériaux et formes de marqueur pour localisation à marqueur magnétique |
CA3097061A1 (fr) * | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Reduction de la viscosite de formulations de proteines hautement concentrees |
CN110327292A (zh) * | 2019-08-11 | 2019-10-15 | 天津乾丰瑞科技有限公司 | 一种盐酸法舒地尔注射制剂及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754523A (fr) * | 1969-08-06 | 1971-02-08 | Beecham Group Ltd | Vaccins |
DK155714C (da) * | 1978-07-04 | 1989-10-30 | Nyegaard & Co As | Fremgangsmaade til fremstilling af en steril, injicerbar, fysiologisk acceptabel oploesning af et roentgenkontrastmiddel, samt en oploesning af roentgenkontrastmidlet til brug ved fremgangsmaaden |
WO1982003773A1 (fr) * | 1981-04-27 | 1982-11-11 | Baxter Travenol Lab | Solution de dialyse contenant du glucose, des acides amines et de l'insuline |
EP0185759B2 (fr) * | 1984-06-22 | 2004-06-02 | Btg International Limited | Solutions electrolytiques et leur utilisation (in vivo) |
IE60901B1 (en) * | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
GB8906130D0 (en) * | 1989-03-17 | 1989-05-04 | Nycomed As | Compositions |
JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
DE59007142D1 (de) | 1990-01-18 | 1994-10-20 | Cereria Amos Sgarbi Spa | Grablicht. |
GB9020091D0 (en) * | 1990-09-14 | 1990-10-24 | Nycomed As | Contrast media |
DE4135193C1 (fr) * | 1991-10-22 | 1993-03-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | |
IT1256248B (it) * | 1992-12-24 | 1995-11-29 | Bracco Spa | Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x |
WO1995026331A1 (fr) * | 1994-03-25 | 1995-10-05 | Centro Investigacion Justesa Imagen, S.A. | Nouveaux dimeres iodes non-ioniques, utiles en tant qu'agents de contraste aux rayons x, procede de preparation, et compositions pharmaceutiques les contenant |
DE4446694A1 (de) * | 1994-12-09 | 1996-06-13 | Schering Ag | Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung |
-
1997
- 1997-01-27 IL IL12467697A patent/IL124676A0/xx unknown
- 1997-01-27 EP EP97914098A patent/EP0876140B1/fr not_active Expired - Lifetime
- 1997-01-27 DE DE19703816A patent/DE19703816A1/de not_active Withdrawn
- 1997-01-27 HU HU9901355A patent/HUP9901355A3/hu unknown
- 1997-01-27 CA CA002244209A patent/CA2244209C/fr not_active Expired - Fee Related
- 1997-01-27 CN CN97191871A patent/CN1209751A/zh active Pending
- 1997-01-27 SK SK1013-98A patent/SK101398A3/sk unknown
- 1997-01-27 KR KR10-1998-0705697A patent/KR100505772B1/ko not_active IP Right Cessation
- 1997-01-27 WO PCT/DE1997/000170 patent/WO1997026862A2/fr not_active Application Discontinuation
- 1997-01-27 DK DK97914098T patent/DK0876140T3/da active
- 1997-01-27 AT AT97914098T patent/ATE251893T1/de not_active IP Right Cessation
- 1997-01-27 JP JP9526441A patent/JP2000505789A/ja not_active Ceased
- 1997-01-27 PT PT97914098T patent/PT876140E/pt unknown
- 1997-01-27 AU AU21504/97A patent/AU2150497A/en not_active Abandoned
- 1997-01-27 CZ CZ982348A patent/CZ234898A3/cs unknown
- 1997-01-27 ES ES97914098T patent/ES2208884T3/es not_active Expired - Lifetime
- 1997-01-27 BR BR9707081A patent/BR9707081A/pt not_active IP Right Cessation
- 1997-01-27 PL PL97328199A patent/PL328199A1/xx unknown
- 1997-01-27 DE DE59710863T patent/DE59710863D1/de not_active Expired - Fee Related
-
1998
- 1998-07-21 BG BG102644A patent/BG62913B1/bg unknown
- 1998-07-24 NO NO983438A patent/NO983438L/no not_active Application Discontinuation
-
2000
- 2000-02-14 US US09/504,108 patent/US6638913B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2208884T3 (es) | 2004-06-16 |
IL124676A0 (en) | 1998-12-06 |
KR19990081979A (ko) | 1999-11-15 |
CZ234898A3 (cs) | 1998-11-11 |
PT876140E (pt) | 2004-02-27 |
WO1997026862A2 (fr) | 1997-07-31 |
CN1209751A (zh) | 1999-03-03 |
CA2244209A1 (fr) | 1997-07-31 |
BR9707081A (pt) | 1999-05-25 |
DK0876140T3 (da) | 2003-12-15 |
DE19703816A1 (de) | 1997-08-07 |
BG102644A (en) | 1999-06-30 |
DE59710863D1 (de) | 2003-11-20 |
SK101398A3 (en) | 1998-12-02 |
ATE251893T1 (de) | 2003-11-15 |
WO1997026862A3 (fr) | 1997-10-23 |
KR100505772B1 (ko) | 2005-10-25 |
AU2150497A (en) | 1997-08-20 |
EP0876140B1 (fr) | 2003-10-15 |
NO983438D0 (no) | 1998-07-24 |
HUP9901355A2 (hu) | 1999-08-30 |
EP0876140A2 (fr) | 1998-11-11 |
PL328199A1 (en) | 1999-01-18 |
HUP9901355A3 (en) | 2000-06-28 |
US6638913B1 (en) | 2003-10-28 |
CA2244209C (fr) | 2007-10-23 |
NO983438L (no) | 1998-09-18 |
JP2000505789A (ja) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG62913B1 (bg) | Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане | |
JP7042531B2 (ja) | デオキシコール酸を含む医薬組成物 | |
JP2002504908A (ja) | 安定なインスリン製剤 | |
EA002776B1 (ru) | Фармацевтические композиции, содержащие циклодекстрины и таксоиды | |
JP3723857B2 (ja) | ヒト成長ホルモン含有水性医薬組成物 | |
US6440934B1 (en) | Angiogenically effective unit dose of FGF-2 and method of use | |
IE64080B1 (en) | Pharmaceutical for subcutaneous administration containing polypeptides | |
JPH0714882B2 (ja) | 循環器系ショックに対する高浸透圧等塩素性製剤 | |
US20200370025A1 (en) | Acute Respiratory Distress Syndrome Therapeutic Agent | |
JP2005532288A (ja) | アロステリックエフェクター化合物を含んだ安定製剤の製造と使用 | |
US6720011B1 (en) | Injectable composition for cancer treatment | |
WO2001041793A1 (fr) | Formulation stable d'interferon en solution, son procede de preparation et ses applications | |
EP0124018B1 (fr) | Préparation pharmaceutique contenant de la fibrinonectine purifiée | |
US10238717B2 (en) | Parenteral glucagon formulations | |
US20220226369A1 (en) | Ethanol hardener and use thereof | |
JPH06247872A (ja) | 高濃度tcf製剤 | |
EP2106791A1 (fr) | Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations | |
CA2416600A1 (fr) | Preparation lyophilisee de tetrahydrate monosodique de n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine et procede permettant de produire cette preparation | |
US20030166550A1 (en) | Angiogenically effective unit dose of FGF-2 and method of use | |
JP3022915B2 (ja) | 癌転移抑制剤 | |
AU763521B2 (en) | Improved concentrated injection and infusion solutions for intravascular use | |
JP2654518B2 (ja) | 肝細胞増殖促進剤 | |
KR20230160261A (ko) | 급성 허혈성 뇌졸중을 치료하는 dc009 | |
JP2023553106A (ja) | 改善された凍結乾燥製剤 | |
PT85848B (en) | Process for the preparation of pharmaceutical compounds with thrombolitic activity containing an urokinase and pro-urokinase synergic mixture |